SARS-CoV-2 JN.1衍生株KP.3、KP.3.1.1、LB.1和XEC的中和抗体逃逸
本研究评估了接种七剂BNT162b2(含XBB.1.5单价疫苗)的医护人员对JN.1及其衍生株的中和抗体应答。在未感染过COVID-19的个体中,KP.3.1.1和LB.1表现出显著免疫逃逸,而既往感染者对所有变异株均维持中和活性。基于JN.1的免疫可诱导对新兴变异株的强效交叉中和活性。
要点
- 未感染过COVID-19者中,KP.3.1.1和LB.1呈现显著免疫逃逸。
- 既往感染者对所有受试变异株均维持中和活性。
- JN.1基础免疫可诱导对新兴变异株的强效交叉中和活性。
核心结论
- 这些发现支持基于JN.1疫苗的潜在有效性,同时强调需持续监测和疫苗优化。
研究设计与样本
- 研究纳入接种七剂BNT162b2(含XBB.1.5单价疫苗)的医护人员,评估其对JN.1及衍生株KP.3、KP.3.1.1、LB.1和XEC的中和抗体应答。
主要发现
- 在未感染过COVID-19的个体中,KP.3.1.1和LB.1表现出显著免疫逃逸,而既往感染者对所有变异株均维持中和活性。
- 基于JN.1的免疫可诱导对新兴变异株的强效交叉中和活性。
- 刺突蛋白第31位单个氨基酸缺失可能与增强的免疫逃逸相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including the XBB.1.5 monovalent vaccine. In COVID-19-naïve individuals, KP.3.1.1 and LB.1 showed substantial immune escape, whereas previously infected individuals maintained neutralization activity against all variants. We also demonstrated that JN.1-based immunization induces robust cross-neutralizing activity against emerging variants. A single amino acid deletion at position 31 in the spike protein may be associated with enhanced immune evasion. These findings support the potential effectiveness of JN.1-based vaccines while highlighting the need for continued surveillance and vaccine optimization.
引用
- Sano K, Miyakawa K, Kato H, et al. Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC. Vaccine. 2025. PMID: 40639176. doi:10.1016/j.vaccine.2025.127472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。